Last Updated: November 19, 2026

CLINICAL TRIALS PROFILE FOR PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE

« Back to Dashboard


All Clinical Trials for PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00141817 ↗ Study Evaluating Pantoprazole in Children With GERD Completed Wyeth is now a wholly owned subsidiary of Pfizer Phase 3 2005-08-01 The purpose of this study is to characterize the PK profile, safety and tolerability of single and multiple doses of pantoprazole in children aged 1 through 11 years with endoscopically proven GERD.
NCT00259012 ↗ Study Evaluating Pantoprazole Sodium Enteric-Coated Spheroid Suspension In Infants With Presumed GERD Completed Nycomed Phase 3 2005-11-01 The purpose of this study is to characterize the pharmacokinetic (PK) and pharmacodynamic (PD) profiles to determine the safety and tolerability of single and multiple doses of pantoprazole in infants aged 1 through 11 months.
NCT00259012 ↗ Study Evaluating Pantoprazole Sodium Enteric-Coated Spheroid Suspension In Infants With Presumed GERD Completed Wyeth is now a wholly owned subsidiary of Pfizer Phase 3 2005-11-01 The purpose of this study is to characterize the pharmacokinetic (PK) and pharmacodynamic (PD) profiles to determine the safety and tolerability of single and multiple doses of pantoprazole in infants aged 1 through 11 months.
NCT00300755 ↗ Study Evaluating Pantoprazole in Children With Gastroesophageal Reflux Disease (GERD) Completed Nycomed Phase 3 2006-05-01 To evaluate the clinical outcomes of treatment with oral pantoprazole in children 1 through 5 years of age with endoscopically proven symptomatic GERD.
NCT00300755 ↗ Study Evaluating Pantoprazole in Children With Gastroesophageal Reflux Disease (GERD) Completed Wyeth is now a wholly owned subsidiary of Pfizer Phase 3 2006-05-01 To evaluate the clinical outcomes of treatment with oral pantoprazole in children 1 through 5 years of age with endoscopically proven symptomatic GERD.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE

Condition Name

Condition Name for PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE
Intervention Trials
Gastroesophageal Reflux 7
Healthy 7
Drug Interaction 1
Postperfusion Syndrome 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE
Intervention Trials
Gastroesophageal Reflux 8
Esophagitis, Peptic 5
Malnutrition 3
Ulcer 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE

Trials by Country

Trials by Country for PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE
Location Trials
United States 111
Canada 10
India 7
Germany 4
South Africa 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE
Location Trials
Texas 7
Kentucky 6
New York 5
Illinois 5
Florida 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE

Clinical Trial Phase

Clinical Trial Phase for PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE
Clinical Trial Phase Trials
Phase 4 2
Phase 3 8
Phase 2 1
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE
Clinical Trial Phase Trials
Completed 21
Unknown status 1
Not yet recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE

Sponsor Name

Sponsor Name for PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE
Sponsor Trials
Wyeth is now a wholly owned subsidiary of Pfizer 7
Teva Pharmaceuticals USA 2
Dr. Reddy's Laboratories Limited 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE
Sponsor Trials
Industry 22
Other 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial
Last updated: May 2, 2026

Pantoprazole Sodium in 0.9% Sodium Chloride: Clinical Status, Market Read-Through, and Demand Projection

What product is this and how is it positioned?

Pantoprazole sodium in 0.9% sodium chloride is an IV proton pump inhibitor (PPI) presentation. Clinically, it is used for indications where oral administration is not feasible or where clinicians require rapid acid suppression (most commonly GERD/esophagitis, stress-related mucosal disease risk management, and GI bleeding settings depending on labeling per region).

Core practical attributes for market behavior:

  • Dose form: IV solution (pantoprazole salt in normal saline, 0.9% NaCl).
  • Use case: hospital acute care and GI bleeding pathways where IV PPIs are standard of care.
  • Switchability: when patients can transition to oral therapy, treatment duration in IV form tends to be shorter, compressing total IV units per episode.

What do clinical trials updates show?

No complete, verifiable clinical trials update specific to “pantoprazole sodium in 0.9% sodium chloride” (as a distinct formulation product) is available in the provided information set. Without verified study-level facts (trial IDs, registry entries, endpoints, timelines), a complete clinical update cannot be stated in an actionable, citation-backed way.

What can be concluded from the therapeutic class only (not a formulation-specific trials update):

  • Pantoprazole is widely studied and used across acute GI indications through class-level experience.
  • Clinical innovation for PPIs has trended toward new molecules, new delivery systems, and biosimilar/generic competitive dynamics, rather than incremental reformulations of the same IV pantoprazole salt in saline.

Therefore, the only defensible “clinical trials update” for investment or R&D decisions here is the market-relevant point: formulation identity rarely changes prescribing behavior if bioequivalence and IV stability are met.


What is the market structure for IV pantoprazole?

The market for IV PPIs is shaped by:

  • Acute care utilization (hospital admissions, emergency GI bleeding protocols, ICU stress ulcer prophylaxis).
  • Therapeutic standardization (order sets often reference IV PPI use).
  • Substitution to lower-cost alternatives (multiple PPIs compete; generics drive pricing).
  • Constrained IV length of therapy (oral switch after stabilization).

From a business lens, IV pantoprazole competes less on “clinical novelty” and more on:

  1. Acquisition cost per dose
  2. Availability and supply reliability
  3. Formulary adoption
  4. Patient throughput impact (drug readiness, pharmacy handling, packaging)

In most countries, IV pantoprazole has faced generic entry cycles that compress unit economics. These cycles usually track to:

  • Expiry of originator patents for pantoprazole itself (not necessarily the IV saline presentation).
  • Subsequent approvals for generic IV solutions in equivalent strengths.

How does demand typically evolve across hospitals?

Demand for IV pantoprazole behaves like a hospital episodic medication:

  • GERD and esophagitis: IV use is concentrated among patients who cannot take oral therapy.
  • GI bleeding protocols: IV PPI use spikes in early management windows.
  • Stress ulcer prophylaxis: ICU and high-risk settings create steady baseline demand, with practice variation.

A “projection” that does not anchor to explicit unit volumes by region, hospital discharge counts, or registry-to-market conversions cannot be stated without inventing numbers.


What demand projection can be made without overstating precision?

A defensible market projection framework for “pantoprazole sodium in 0.9% sodium chloride” can be expressed as drivers and likely directionality, not numeric forecasts:

Primary demand drivers (positive):

  • Rising hospitalizations in acute GI and ICU settings (where IV acid suppression is clinically needed).
  • Persistent clinician preference for IV PPIs where oral intake is delayed.
  • Continued protocolization of GI bleeding management.

Primary demand constraints (negative):

  • Generic competition compressing net pricing.
  • Shorter IV courses due to early oral switch once clinically feasible.
  • Substitution to other IV PPIs with stronger formulary positions.

Projection direction (base-case):

  • Volume: modest growth or stable-to-slightly up over multi-year horizons, driven by hospital consumption needs.
  • Value: flattish to down in many markets due to generic pricing pressure.
  • Share: may shift between IV PPI molecules and between suppliers of pantoprazole depending on tender outcomes.

This directionality aligns with how IV hospital injectables typically behave once generics establish cost leadership.


What should R&D and investment teams watch in formulation-level competition?

Even when clinical effects are class-consistent, formulation and supply execution can decide share.

Watch indicators:

  • Tender pricing trends for pantoprazole IV across large hospital systems.
  • Stockout incidence and alternative substitution at pharmacy level.
  • Stability and handling attributes that affect pharmacy workflow (packaging, reconstitution, shelf life).
  • Regulatory actions around manufacturing sites and product quality reviews.

Key Takeaways

  • Pantoprazole sodium in 0.9% sodium chloride is a hospital IV PPI presentation used where oral administration is not feasible and in acute GI pathways.
  • A formulation-specific clinical trials update cannot be stated without verifiable trial registry and publication details.
  • Market behavior is driven more by hospital adoption, tender pricing, and generics than by incremental clinical differentiation.
  • The most defensible projection is stable-to-mildly growing IV volume with pricing pressure and supplier share volatility driven by tenders and substitution.

FAQs

1) Does IV pantoprazole demand grow because of new clinical evidence?

Demand grows primarily through hospital use patterns and protocols rather than new evidence, once clinicians already standardize IV PPI management.

2) What limits IV pantoprazole prescriptions per patient?

The major limiter is early clinical stabilization and oral switch, which shortens IV exposure duration.

3) Is the saline presentation a major determinant of market share?

Usually not if bioequivalence and IV handling meet requirements. Market share tends to track price, availability, and formulary position.

4) Where is usage concentrated?

Usage concentrates in acute hospital settings: GI bleeding pathways, ICU-related stress ulcer prophylaxis, and patients unable to take oral therapy.

5) What creates value erosion in this product category?

Generic entry and tender-driven pricing compress net pricing faster than demand growth can compensate.


References

[1] World Health Organization. ATC classification system. WHO. https://www.whocc.no/atc/ (accessed 2026-05-03)
[2] U.S. FDA. Drug trials snapshots and product labeling resources. https://www.fda.gov/drugs (accessed 2026-05-03)
[3] European Medicines Agency. Medicines and product information. https://www.ema.europa.eu/en/medicines (accessed 2026-05-03)

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.